BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37844543)

  • 1. Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease.
    Kishimoto TK; Fournier M; Michaud A; Rizzo G; Roy C; Capela T; Nukolova N; Li N; Doyle L; Fu FN; VanDyke D; Traber PG; Spangler JB; Leung SS; Ilyinskii PO
    J Autoimmun; 2023 Nov; 140():103125. PubMed ID: 37844543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of the Tolerogenic Phenotype in the Liver by ImmTOR Nanoparticles.
    Ilyinskii PO; Roy CJ; LePrevost J; Rizzo GL; Kishimoto TK
    Front Immunol; 2021; 12():637469. PubMed ID: 34113339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies.
    Kishimoto TK
    Front Immunol; 2020; 11():969. PubMed ID: 32508839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
    Peterson LB; Bell CJM; Howlett SK; Pekalski ML; Brady K; Hinton H; Sauter D; Todd JA; Umana P; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Klein C; Hosse RJ; Wicker LS
    J Autoimmun; 2018 Dec; 95():1-14. PubMed ID: 30446251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo Expansion of Antigen-Specific Regulatory T Cells through Staggered Fc.IL-2 Mutein Dosing and Antigen-Specific Immunotherapy.
    Pham MN; Khoryati L; Jamison BL; Hayes E; Sullivan JM; Campbell DJ; Gavin MA
    Immunohorizons; 2021 Sep; 5(9):782-791. PubMed ID: 34583939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.
    Todd JA; Evangelou M; Cutler AJ; Pekalski ML; Walker NM; Stevens HE; Porter L; Smyth DJ; Rainbow DB; Ferreira RC; Esposito L; Hunter KM; Loudon K; Irons K; Yang JH; Bell CJ; Schuilenburg H; Heywood J; Challis B; Neupane S; Clarke P; Coleman G; Dawson S; Goymer D; Anselmiova K; Kennet J; Brown J; Caddy SL; Lu J; Greatorex J; Goodfellow I; Wallace C; Tree TI; Evans M; Mander AP; Bond S; Wicker LS; Waldron-Lynch F
    PLoS Med; 2016 Oct; 13(10):e1002139. PubMed ID: 27727279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low CD25 on autoreactive Tregs impairs tolerance via low dose IL-2 and antigen delivery.
    Hotta-Iwamura C; Benck C; Coley WD; Liu Y; Zhao Y; Quiel JA; Tarbell KV
    J Autoimmun; 2018 Jun; 90():39-48. PubMed ID: 29439835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ImmTOR nanoparticles enhance AAV transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia.
    Ilyinskii PO; Michaud AM; Rizzo GL; Roy CJ; Leung SS; Elkins SL; Capela T; Chowdhury A; Li L; Chandler RJ; Manoli I; Andres-Mateos E; Johnston LPM; Vandenberghe LH; Venditti CP; Kishimoto TK
    Mol Ther Methods Clin Dev; 2021 Sep; 22():279-292. PubMed ID: 34485611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose IL-2 therapy in autoimmune diseases: An update review.
    Zhang R; Zhao Y; Chen X; Zhuang Z; Li X; Shen E
    Int Rev Immunol; 2024 May; 43(3):113-137. PubMed ID: 37882232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treg Enhancing Therapies to Treat Autoimmune Diseases.
    Eggenhuizen PJ; Ng BH; Ooi JD
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory T cells suppress the formation of potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2.
    Tsyklauri O; Chadimova T; Niederlova V; Kovarova J; Michalik J; Malatova I; Janusova S; Ivashchenko O; Rossez H; Drobek A; Vecerova H; Galati V; Kovar M; Stepanek O
    Elife; 2023 Jan; 12():. PubMed ID: 36705564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How GRAIL controls Treg function to maintain self-tolerance.
    Fathman CG; Yip L; Gómez-Martín D; Yu M; Seroogy CM; Hurt CR; Lin JT; Jenks JA; Nadeau KC; Soares L
    Front Immunol; 2022; 13():1046631. PubMed ID: 36569931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revealing the specificity of regulatory T cells in murine autoimmune diabetes.
    Spence A; Purtha W; Tam J; Dong S; Kim Y; Ju CH; Sterling T; Nakayama M; Robinson WH; Bluestone JA; Anderson MS; Tang Q
    Proc Natl Acad Sci U S A; 2018 May; 115(20):5265-5270. PubMed ID: 29712852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene Therapy With Regulatory T Cells: A Beneficial Alliance.
    Biswas M; Kumar SRP; Terhorst C; Herzog RW
    Front Immunol; 2018; 9():554. PubMed ID: 29616042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Readministration of high-dose adeno-associated virus gene therapy vectors enabled by ImmTOR nanoparticles combined with B cell-targeted agents.
    Ilyinskii PO; Roy C; Michaud A; Rizzo G; Capela T; Leung SS; Kishimoto TK
    PNAS Nexus; 2023 Nov; 2(11):pgad394. PubMed ID: 38024395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective activation and expansion of regulatory T cells using lipid encapsulated mRNA encoding a long-acting IL-2 mutein.
    de Picciotto S; DeVita N; Hsiao CJ; Honan C; Tse SW; Nguyen M; Ferrari JD; Zheng W; Wipke BT; Huang E
    Nat Commun; 2022 Jul; 13(1):3866. PubMed ID: 35790728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerogenic Nanoparticles Induce Antigen-Specific Regulatory T Cells and Provide Therapeutic Efficacy and Transferrable Tolerance against Experimental Autoimmune Encephalomyelitis.
    LaMothe RA; Kolte PN; Vo T; Ferrari JD; Gelsinger TC; Wong J; Chan VT; Ahmed S; Srinivasan A; Deitemeyer P; Maldonado RA; Kishimoto TK
    Front Immunol; 2018; 9():281. PubMed ID: 29552007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of FOXP3
    Mohr A; Atif M; Balderas R; Gorochov G; Miyara M
    Clin Exp Immunol; 2019 Jul; 197(1):24-35. PubMed ID: 30830965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations.
    Terry LV; Oo YH
    Front Immunol; 2020; 11():565518. PubMed ID: 33072105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells.
    Nayak S; Cao O; Hoffman BE; Cooper M; Zhou S; Atkinson MA; Herzog RW
    J Thromb Haemost; 2009 Sep; 7(9):1523-32. PubMed ID: 19583824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.